IP Library Granted Patent US 8,932,846
Granted Patent B2
US 8,932,846 · App. 12/664,485 · Granted Jan 13, 2015

Unmarked recombinant intracellular pathogen immunogenic compositions expressing high levels of recombinant proteins

Inventors: Marcus A. Horwitz (Los Angeles, CA); Michael V. Tullius (Encino, CA)
Assignee: The Regents of the University of California
A61K39/04A61K2039/523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,932,846
App. No.
12/664,485
Granted
Jan 13, 2015
Kind
B2
Abstract

Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker (“unmarked”).

Claims (6)

1. An immunogenic composition comprising a recombinant Bacille Calmette Guérin (BCG) wherein said recombinant BCG expresses at least one Mycobacteria major extracellular protein selected from 23.5 kDa protein, 30 kDa protein, 32A kDa protein, and 32B kDa protein; wherein a nucleic acid sequence encoding for said at least one Mycobacteria major extracellular protein is incorporated into said recombinant BCG's chromosome(s) under a strong promoter such that said Mycobacteria major extracellular protein is over-expressed, and the recombinant BCG does not harbor an antibiotic resistance marker.

2. The immunogenic composition of claim 1 wherein said least one Mycobacteria major extracellular protein is from Mycobacterium bovis, M. tuberculosis, M. leprae, M. kansasii, M. avium , or Mycobacterium sp.

3. The immunogenic composition according to claim 1 wherein said recombinant BCG is growth regulatable.

4. The immunogenic composition according to claim 2 wherein said recombinant BCG further expresses at least one Mycobacteria major extracellular protein selected from 12 kDa protein, 14 kDa protein, 16 kDa protein, 24 kDa protein, 45 kDa protein, 58 kDa protein, 71 kDa protein, 80 kDa protein, and 110 KD protein.

5. The immunogenic composition according to claim 1 further comprising at least one cytokine, wherein the cytokine is interferon gamma, interleukin-2, interleukin-12, soluble interleukin-4 receptor, and granulocyte macrophage colony stimulating factor, or combinations thereof.

6. The immunogenic composition according to claim 1 wherein said promoter is the promoter for a M. tuberculosis rrs gene or a shortened derivative thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 9, 2010
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024805/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2009
From: HORWITZ, MARCUS A.; TULLIUS, MICHAEL V.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023647/0788 →
Continuity (2)
Provisional Application 60944051 · Jun 14, 2007
Related Publication 20100183547A1 · Jul 22, 2010